About the IMF:
Founded in 1990, the International Myeloma Foundation (IMF) was the first organ-
ization dedicated solely to the field of multiple myeloma, and today remains the
The IMF Presents
largest. The IMF reaches out to a global membership of more than 75,000, pro-
viding a broad spectrum of services to patients, caregivers and healthcare
providers. The IMF funds a research grant program designed to increase the num-
A LIVE INTERACTIVE CME TELECONFERENCE
ber of scientists working on a cure for myeloma, sponsors a wide range of educa-
tional seminars and workshops, offers complimentary information on treatment
and management of the disease, publishes a free-of-charge newsletter Myeloma
Today, and manages a patient directory and a network of more than 50 myeloma
PERSPECTIVES IN MULTIPLE MYELOMA:
support groups. For more information about IMF programs and services, go to
www.myeloma.org or call (800) 452-CURE.
Directions Toward New
IMF Contact Info:
Therapeutic Options
International Myeloma Foundation
12650 Riverside Drive, Ste. 206
North Hollywood, CA 91607
Phone: (800) 452-CURE
Phone: (818) 487-7455
Fax: (818) 487-7454
Rationale
The
Email: TheIMF@myeloma.org
Website: www.myeloma.org
and Future
Clinical
Directions
Experience
NO POSTAGE
ELECONFERENCE
NECESSARY
T
IF MAILED
IN THE
James Berenson, MD
Mohamad Hussein, MD
UNITED STATES
Cedars-Sinai Medical Center
The Cleveland Clinic
BUSINESS REPLY MAIL
:
CME
FIRST-CLASS MAIL
PERMIT NO. 821
STAMFORD, CT
MA
POSTAGE WILL BE PAID BY ADDRESSEE
Inc.
212
IN
OL
S
CTIVE
AOI COMMUNICATIONS, INC.
Suite
YE
oward
1 STAMFORD LANDING
M
T
62 SOUTHFIELD AVENUE, SUITE 212
venue,
TIVE
E
NTERA
Tuesday, November 6, 2001
STAMFORD CT 06913-2030
A
06902
C
L
I
Landing
E
P
herapeutic
Communications,
CT
PS
T
Sponsored by Postgraduate Institute for
OI
R
LTI
Medicine through an
A
Southfield
E
U
irections
ew
ptions
unrestricted educational grant from
LIVE
Stamford
c/o
1
62
Stamford,
P
M
D
N
O
Cell Therapeutics, Inc.
A
Target Audience
PERSPECTIVES IN MULTIPLE MYELOMA:
This activity has been designed to meet the educational needs of general practicing oncologists
and hematologists involved in the treatment of patients with multiple myeloma.
Directions Toward New Therapeutic Options
Learning Objectives
Tuesday, November 6, 2001
Upon completion of this activity, the participant should be able to:
· Define and discuss prognostic factors for multiple myeloma
· Describe the role of innovative therapies in the treatment of multiple myeloma
Rationale
The Clinical
· Review current evolving preclinical and early clinical data and therapeutic strategies for the
and Future
Experience
management of multiple myeloma, including the use of arsenic trioxide and other novel
compounds
Directions
Registration
· To register by US MAIL: Complete and return the attached reply card
Accreditation Statement
· To register by FAX: Complete and fax the attached reply card to
This activity has been planned and implemented in accordance with the Essential Areas and Policies
of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsor-
(203) 406-1726
ship of Postgraduate Institute for Medicine and AOI Communications, Inc. The Postgraduate Institute
· To register by E-MAIL: l.fischer@accessoncology.com
for Medicine is accredited by the ACCME to provide continuing medical education for physicians
James Berenson, MD
Mohamad Hussein, MD
and takes responsibility for the content, quality, and scientific integrity of this CME activity.
Cedars-Sinai Medical Center
The Cleveland Clinic
Designation Statement
The Postgraduate Institute for Medicine designates this educational activity for a maximum of 1 hour
Program Workbooks for registrants will arrive approximately one week prior to
TIME OF TELECONFERENCE
in category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim
the teleconference.
only those hours of credit that he/she actually spent in the activity.
PROGRAM ID
EASTERN CENTRAL
MOUNTAIN
PACIFIC
For additional information, please do not hesitate to contact
Faculty Disclosure Statement
A
12:30 P.M. 11:30 P.M.
10:30 A.M.
9:30 A.M.
Lauren Fischer at AOI COMMUNICATIONS, INC. at 650-321-6068
All faculty participating in Continuing Medical Education activities sponsored by Postgraduate
Institute of Medicine are expected to disclose to the audience any real or apparent commercial
B
1:30 P.M.
12:30 P.M.
11:30 A.M.
10:30 A.M.
financial affiliations related to the content of their presentations/materials.
C
3:30 P.M.
2:30 P.M.
1:30 P.M.
12:30 P.M.
Support Statement
(PLEASE PRINT CLEARLY)
This CME activity is supported by an unrestricted educational grant from Cell Therapeutics, Inc. (cti)
Program Description
For Further Information
Perspectives in Multiple Myeloma will provide oncologists and hematologists the rare opportu-
PERSPECTIVES IN MULTIPLE MYELOMA:
nity to engage in state of the art discussion* with specialists in the field of Multiple Myeloma.
· Please contact Lauren Fischer of AOI Communications, Inc. at (650) 321-6068 or via email
This program will presented in two parts and will offer insight from two different perspectives:
Directions Toward New Therapeutic Options
at L.fischer@accessoncology.com
Treatment and Research.
Tuesday, November 6, 2001
In an effort to improve patient outcomes, this program, via interactive discussion, will educate
and inform clinical oncologists and hematologists about the research and clinical aspects asso-
ciated with the identification of novel targets and strategies that lead to the development of
PROGRAM ID (circle one): AB
C
innovative therapeutic options for the treatment of multiple myeloma.
WE INVITE YOU TO REGISTER NOW and take advantage of this opportunity to interact with
Name__________________________________________Title (MD or other)__________
the distinguished faculty and your colleagues regarding cutting edge research associated with
Affiliation______________________________________________________________
the identification of novel targets and strategies for drug discovery, clinical implications of
innovative therapeutic options, and the latest clinical data related to the management of
Address________________________________________________________________
Multiple Myeloma.
City_________________________________________State_____Zip______________
*a toll free dial in number will be provided to participants upon receipt of registration information
Phone____________________________Fax___________________________________
Email address____________________________________________________________
Sponsored by Postgraduate Institute for
Medicine through an unrestricted
educational grant from Cell Therapeutics, Inc.
Sponsored by Postgraduate Institute for Medicine through an
unrestricted educational grant from Cell Therapeutics, Inc.